Teladoc Health Statistics
Total Valuation
Teladoc Health has a market cap or net worth of $1.06 billion. The enterprise value is $1.32 billion.
| Market Cap | 1.06B |
| Enterprise Value | 1.32B |
Important Dates
The next confirmed earnings date is Wednesday, October 28, 2026, after market close.
| Earnings Date | Oct 28, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Teladoc Health has 181.68 million shares outstanding. The number of shares has increased by 2.97% in one year.
| Current Share Class | 181.68M |
| Shares Outstanding | 181.68M |
| Shares Change (YoY) | +2.97% |
| Shares Change (QoQ) | +1.06% |
| Owned by Insiders (%) | 0.69% |
| Owned by Institutions (%) | 85.58% |
| Float | 180.43M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.42 |
| Forward PS | 0.44 |
| PB Ratio | 0.81 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 4.16 |
| P/OCF Ratio | 4.04 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 20.41, with an EV/FCF ratio of 5.19.
| EV / Earnings | n/a |
| EV / Sales | 0.53 |
| EV / EBITDA | 20.41 |
| EV / EBIT | n/a |
| EV / FCF | 5.19 |
Financial Position
The company has a current ratio of 0.83, with a Debt / Equity ratio of 0.79.
| Current Ratio | 0.83 |
| Quick Ratio | 0.73 |
| Debt / Equity | 0.79 |
| Debt / EBITDA | 13.27 |
| Debt / FCF | 4.08 |
| Interest Coverage | -7.30 |
Financial Efficiency
Return on equity (ROE) is -12.99% and return on invested capital (ROIC) is -3.79%.
| Return on Equity (ROE) | -12.99% |
| Return on Assets (ROA) | -3.22% |
| Return on Invested Capital (ROIC) | -3.79% |
| Return on Capital Employed (ROCE) | -10.58% |
| Weighted Average Cost of Capital (WACC) | 8.85% |
| Revenue Per Employee | $444,550 |
| Profits Per Employee | -$31,678 |
| Employee Count | 5,600 |
| Asset Turnover | 0.88 |
| Inventory Turnover | 23.07 |
Taxes
| Income Tax | -5.20M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -29.58% in the last 52 weeks. The beta is 2.14, so Teladoc Health's price volatility has been higher than the market average.
| Beta (5Y) | 2.14 |
| 52-Week Price Change | -29.58% |
| 50-Day Moving Average | 6.27 |
| 200-Day Moving Average | 6.51 |
| Relative Strength Index (RSI) | 43.91 |
| Average Volume (20 Days) | 3,677,870 |
Short Selling Information
The latest short interest is 30.10 million, so 16.57% of the outstanding shares have been sold short.
| Short Interest | 30.10M |
| Short Previous Month | 25.34M |
| Short % of Shares Out | 16.57% |
| Short % of Float | 16.68% |
| Short Ratio (days to cover) | 8.86 |
Income Statement
In the last 12 months, Teladoc Health had revenue of $2.49 billion and -$177.40 million in losses. Loss per share was -$0.99.
| Revenue | 2.49B |
| Gross Profit | 1.72B |
| Operating Income | -145.65M |
| Pretax Income | -182.59M |
| Net Income | -177.40M |
| EBITDA | 64.56M |
| EBIT | -145.65M |
| Loss Per Share | -$0.99 |
Balance Sheet
The company has $774.35 million in cash and $1.04 billion in debt, with a net cash position of -$261.86 million or -$1.44 per share.
| Cash & Cash Equivalents | 774.35M |
| Total Debt | 1.04B |
| Net Cash | -261.86M |
| Net Cash Per Share | -$1.44 |
| Equity (Book Value) | 1.31B |
| Book Value Per Share | 7.21 |
| Working Capital | -233.37M |
Cash Flow
In the last 12 months, operating cash flow was $261.18 million and capital expenditures -$7.49 million, giving a free cash flow of $253.70 million.
| Operating Cash Flow | 261.18M |
| Capital Expenditures | -7.49M |
| Depreciation & Amortization | 210.21M |
| Net Borrowing | n/a |
| Free Cash Flow | 253.70M |
| FCF Per Share | $1.40 |
Margins
Gross margin is 68.97%, with operating and profit margins of -5.85% and -7.13%.
| Gross Margin | 68.97% |
| Operating Margin | -5.85% |
| Pretax Margin | -7.33% |
| Profit Margin | -7.13% |
| EBITDA Margin | 2.59% |
| EBIT Margin | -5.85% |
| FCF Margin | 10.19% |
Dividends & Yields
Teladoc Health does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -2.97% |
| Shareholder Yield | -2.97% |
| Earnings Yield | -16.81% |
| FCF Yield | 24.03% |
Analyst Forecast
The average price target for Teladoc Health is $7.59, which is 30.64% higher than the current price. The consensus rating is "Hold".
| Price Target | $7.59 |
| Price Target Difference | 30.64% |
| Analyst Consensus | Hold |
| Analyst Count | 23 |
| Revenue Growth Forecast (3Y) | -1.71% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Teladoc Health has an Altman Z-Score of -7.25 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -7.25 |
| Piotroski F-Score | 3 |